// App-Quantinova.ai

2014 : Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.

Researchers

Presenter

  • David A. Reardon

Principal Investigators

  • John H. Sampson

  • Solmaz Sahebjam

  • Michael Lim

  • Joachim M. Baehring

  • Gordana Vlahovic

  • Timothy Francis Cloughesy

  • Lewis C. Strauss

  • Robert Raymond Latek

  • Prashni Paliwal

  • Christopher T. Harbison

  • Alfredo Daniel Voloschin

  • Antonio Marcilio Padula Omuro

Medical Centers

  • Dana-Farber Cancer Institute and Harvard University School of Medicine, Boston, MA

  • Duke University Medical Center, Durham, NC

  • Moffitt Cancer Center, Tampa, FL

  • The Johns Hopkins Hospital, Baltimore, MD

  • Yale University School of Medicine, New Haven, CT

  • University of California, Los Angeles, Los Angeles, CA

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Emory University School of Medicine, Atlanta, GA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Temozolomide

  • Ipilimumab

  • Nivolumab

Outcome

  • Unknown

Study Design

  • Randomized

  • Cohort

Phase

  • I

Study Id's

  • NCT02017717

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved